Research and Markets: Breast Cancer Therapeutics: Pipeline Analysis Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015-2023

DUBLIN–(BUSINESS WIRE)–Research and Markets (
has announced the addition of the “Breast
Cancer Therapeutics: Pipeline Analysis Market – Global Industry
Analysis, Size, Share, Growth, Trends and Forecast 2015-2023”

report to their offering.

Based on clinical phases, the breast cancer therapeutics: pipeline
analysis market has been segmented into three major categories: phase I
drug candidates, phase II drug candidates, and phase III drug candidates.

Tabular representation for phase I drug candidates and phase II drug
candidates has been provided, which summarizes information about
promising drug candidates under clinical trials and associated
conditions, sponsors and collaborators, primary outcome measure, time
frame, and status about designated safety issue.

The phase III drug candidates section is further differentiated into
various key molecules that are expected to give promising results. These
molecules include Palbociclib (PD-0332991) + Fulvestrant, NK105, BKM120,
NKTR-102, Neratinib, Olaparib, DOXIL, ABP 980, CT-P6, and Trastuzumab
Emtansine + Pertuzumab.

Commercial analysis for all these molecules is provided by forecasting
the anticipated market revenue from the expected year of
commercialization until 2023. Compound annual growth rate (CAGR %) for
each of these molecules is also provided for the period from the
expected commercialization year to 2023.

A list of recommendations has been provided for new entrants as well as
existing market players to assist in taking strategic initiatives in a
bid to establish a strong pipeline for breast cancer therapeutic drugs.
The report also profiles major players in the breast cancer
therapeutics: pipeline analysis market based on various attributes such
as company overview, financial overview, product portfolio, business
strategies, and recent developments.

Major players profiled in this report include AstraZeneca plc, Eisai
Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG,
GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., and Sanofi.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Executive Summary

Chapter 3 Market Overview

Chapter 4 Global Breast Cancer Therapeutics: Pipeline Analysis, by Drugs
(Phase III)

Chapter 5 Recommendations

Chapter 6 Company Profiles

– AstraZeneca plc

– Eisai Co., Ltd.

– Eli Lilly and Company

– F. Hoffmann-La Roche Ltd.

– GlaxoSmithKline plc

– Novartis International AG

– Pfizer, Inc.

– Sanofi

For more information visit


Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Women’s
, Breast